Buy Rating on Lineage Therapeutics Backed by Roche Collaboration and Solid Financials
TipRanks (Tue, 14-May 4:46 AM ET)
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Business Wire (Thu, 9-May 4:01 PM ET)
Business Wire (Mon, 6-May 8:00 AM ET)
Business Wire (Thu, 2-May 8:00 AM ET)
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
Business Wire (Tue, 30-Apr 8:00 AM ET)
Lineage Announces Changes to Board of Directors
Business Wire (Mon, 29-Apr 4:30 PM ET)
Business Wire (Mon, 1-Apr 8:00 AM ET)
Business Wire (Mon, 18-Mar 8:00 AM ET)
Business Wire (Wed, 13-Mar 8:00 AM ET)
Business Wire (Mon, 11-Mar 8:00 AM ET)
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Lineage Cell Therapeutics trades on the AMEX stock market under the symbol LCTX.
As of May 17, 2024, LCTX stock price climbed to $1.08 with 1,351,400 million shares trading.
LCTX has a beta of 0.63, meaning it tends to be less sensitive to market movements. LCTX has a correlation of 0.02 to the broad based SPY ETF.
LCTX has a market cap of $203.90 million. This is considered a Small Cap stock.
Last quarter Lineage Cell Therapeutics reported $1 million in Revenue and -$.04 earnings per share. This beat revenue expectation by $84,000 and met earnings estimates .
In the last 3 years, LCTX stock traded as high as $3.00 and as low as $.84.
The top ETF exchange traded funds that LCTX belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
LCTX has underperformed the market in the last year with a price return of -20.6% while the SPY ETF gained +30.7%. LCTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.4% and +2.9%, respectively, while the SPY returned +6.3% and +4.8%, respectively.
LCTX support price is $1.00 and resistance is $1.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LCTX stock will trade within this expected range on the day.